Inventor
Weiming Xu
Inventor
San Diego, CA, US
Overview
Patents· 13 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes25%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
C07DHeterocyclic compounds11%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium8%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms8%
G01NInvestigating or analysing materials by determining their chemical or physical properties8%
C07CAcyclic or carbocyclic compounds6%
B01JChemical or physical processes, e.g. catalysis or colloid chemistry3%
C07BGeneral methods of organic chemistry3%
C09KMaterials for miscellaneous applications, not provided for elsewhere3%
PatentTitleYear
10,611,721Method for preparing levobunolol hydrochloride202010,604,466Method for preparing resveratrol compound202010,125,119Series of resveratrol-derivative fluorescently labeled molecules and synthesis method thereof201810,004,735Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines20189,737,535'Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines'20179,555,033'Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors'20179,557,338'Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activity'20179,155,736'Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity'20158,507,492'Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway'20138,492,381'Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway'20138,394,832'Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders'20138,110,578'Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway'20126,197,509'Method of analyzing DNA using contiguous repeats'2001Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2001Based in Cambridge, GB· patent location history
2012–2018Patents assigned to SIGNAL PHARM LLC (8)· patent assignee history
2012–2017Patents assigned to XU WEIMING (5)· patent assignee history
2012–2017Patents assigned to SANKAR SABITA (4)· patent assignee history
2012–2013Patents assigned to ELSNER JAN (3)· patent assignee history
2012–2013Patents assigned to FULTZ KIMBERLY (3)· patent assignee history
2012–2018Based in San Diego, CA, US· patent location history
2018–2020Based in Hangzhou, CN· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| SIGNAL PHARM LLC | 8 | 2012–2018 |
| XU WEIMINGself | 5 | 2012–2017 |
| SANKAR SABITA | 4 | 2012–2017 |
| ELSNER JAN | 3 | 2012–2013 |
| FULTZ KIMBERLY | 3 | 2012–2013 |
Locations
| Location | Patents | Span |
|---|---|---|
| San Diego, California, US | 9 | 2012–2018 |
| Hangzhou, CN | 3 | 2018–2020 |
| Cambridge, GB | 1 | 2001 |